GlassScriptPhysician profile
Yash Patel
NPI 1205284601
$1,578.88
in general payments reported to CMS, 2019-2025
33 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.33 · 2020: $120 · 2021: $299 · 2022: $161 · 2023: $219 · 2024: $310 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.34 |
| Education | $119.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.25 | 2020-2025 | |
| Amgen INC. | $178.29 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $161.67 | 2020-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Teva Pharmaceuticals USA, INC. | $99.99 | 2025 | |
| Lilly USA, LLC | $90.27 | 2021-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.73 | 2020-2025 | Jardiance |
| Corcept Therapeutics | $55.75 | 2023-2025 | Korlym |
| Abiomed | $44.33 | 2019 | |
| Pfizer INC. | $38.61 | 2021-2025 | |
| Abbott Laboratories | $37.15 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $36.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.23 | 2024-2025 | |
| Axsome Therapeutics, INC. | $30.21 | 2024-2025 | Auvelity |
| Lundbeck LLC | $29.28 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $29.09 | 2023-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28.58 | 2024-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $25.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.86 | 2020-2021 | |
| Irhythm Technologies, INC. | $22.93 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.96 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $20.18 | 2024 | Nexletol |
| Genzyme Corporation | $20.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Biogen, INC. | $19.51 | 2021 | |
| Si-Bone, INC. | $19.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.81 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.64 | 2021 | |
| Astellas Pharma US INC | $14.98 | 2021 | |
| Novo Nordisk INC | $14.68 | 2024 | Wegovy |
| Eisai INC. | $14.61 | 2020 | |
| Exact Sciences Corporation | $14.28 | 2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $12.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yash Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.